Evidence map›Paper›PMID 37082692›Full record

ArticleAnnals of translational medicine2023

Sequence of therapies for advanced BRAFV600E/K melanoma.

Maria Gonzalez-Cao, Rafael Rosell, Salvador Martin Algarra, Teresa Puertolas, Enrique Espinosa

Open access · diamondAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Maria Gonzalez-CaoTranslational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.
Rafael RosellTranslational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.
Salvador Martin AlgarraMedical Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
Teresa PuertolasMedical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Enrique EspinosaMedical Oncology Department, Hospital Universitario La Paz, Madrid, CIBERONC, Spain.
Centro de Investigación Biomédica en Red de Cáncer · ESClinica Universidad de Navarra · ESHospital Universitario Miguel Servet · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESInstituto Oncológico Dr. Rosell · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRAFCTLA-4immunotherapymelanomaprogrammed death 1 (PD-1)

Identifiers

PMID37082692
PMCPMC10113073
OpenAlexW4320716025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.